HONG KONG – Chinese clinical-stage biotech Connect Biopharmaceuticals Ltd., of Suzhou, secured $55 million in a series B financing to move forward its two lead drug candidates, CBP-307 for treating ulcerative colitis and Crohn's disease and CBP-201 for treating atopic dermatitis, to the next stage.
HONG KONG - Chinese clinical-stage biotech Antengene Corp. raised $120 million in series B financing to move forward its lead programs, ATG-008 and ATG-010 (selinexor), for treating blood cancer and liver cancer, respectively.
HONG KONG – With Thursday's nod for Tyvyt (sintilimab injection), a core asset of HKEX-listed Innovent Biologics Inc. to treat classical Hodgkin lymphoma, either relapsed or refractory after two or more lines of systemic chemotherapy, Chinese regulators have approved two homegrown anti-PD-1 monoclonal antibodies in little more than a week.
TAIPEI, Taiwan – Taiwan startup Sinew Pharma Inc. is developing what it hopes will be a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). With an investigational new drug (IND) approval by the U.S. FDA under its belt, Sinew plans to advance its core product to a phase IIb study next year.
TAIPEI, Taiwan – Taiwan startup Sinew Pharma Inc. is developing what it hopes will be a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). With an investigational new drug (IND) approval by the U.S. FDA under its belt, Sinew plans to advance its core product to a phase IIb study next year.
HONG KONG – With Thursday's nod for Tyvyt (sintilimab injection), a core asset of HKEX-listed Innovent Biologics Inc. to treat classical Hodgkin lymphoma, either relapsed or refractory after two or more lines of systemic chemotherapy, Chinese regulators have approved two homegrown anti-PD-1 monoclonal antibodies in little more than a week.
HONG KONG – Shanghai Junshi Biosciences Ltd. (HKG:1877) made a strong debut on the Hong Kong Stock Exchange, helped by China's first marketing approval of a homemade PD-1 monoclonal antibody last week. The biotech company's shares finished their first day of trading, on Dec. 24, up 22.55 percent to HK$23.75 (US$3.03).
HONG KONG – I-Mab Biopharma (Shanghai) Co. Ltd. out-licensed China rights to its long-acting glucagon-like peptide-1 (GLP-1) Fc protein, known as TG-103, to treat diabetes to CSPC Pharmaceutical Group Co. Ltd. for ¥150 million (US$21.7 million). As part of the deal, CSPC paid ¥15 million up front to I-Mab to obtain the exclusive license and will pay another ¥135 million based on the development progress of TG-103 in China as well as royalties.
HONG KONG – Shanghai Junshi Biosciences Ltd. (HKG:1877) made a strong debut on the Hong Kong Stock Exchange, helped by China's first marketing approval of a homemade PD-1 monoclonal antibody last week. The biotech company's shares finished their first day of trading, on Dec. 24, up 22.55 percent to HK$23.75 (US$3.03).
